High LIFR expression levels and low LCN2 expression levels can be used to estimate the effect of sorafenib, and low expression levels of LIFR and high expression levels of LCN2 can be used to help select patients with HCC who may be benefited from combination treatment with sorafenib and LCN2 neutralizing antibodies (Yao et al., 2021). The gene discussed is LIFR; the disease is hepatocellular carcinoma.